<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00865566</url>
  </required_header>
  <id_info>
    <org_study_id>HVTN 505</org_study_id>
    <secondary_id>10753</secondary_id>
    <nct_id>NCT00865566</nct_id>
    <nct_alias>NCT00919789</nct_alias>
  </id_info>
  <brief_title>Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men</brief_title>
  <official_title>Phase 2b, Randomized, Placebo-Controlled Test-of-Concept Trial to Evaluate the Safety and Efficacy of a Multiclade HIV-1 DNA Plasmid Vaccine Followed by a Multiclade HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Adenovirus Type 5 Neutralizing Antibody Negative, Circumcised Men and Male-to-Female (MTF) Transgender Persons, Who Have Sex With Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>HIV Vaccine Trials Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and efficacy of a VRC DNA/rAd5 vaccine
      regimen in healthy, circumcised men and male-to-female (MTF) transgender persons who have sex
      with men.

      NOTES:

      As of April 2013, all vaccinations in this study have been stopped.

      As of June 2017, this study has been closed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In 2007, the Joint United Nations Programme on HIV/AIDS estimated that 33.2 million people
      were living with HIV/AIDS globally. The U.S. HIV prevalence data reported in October 2008 by
      the Centers for Disease Control and Prevention estimate that 1.1 million adults and
      adolescents were living with diagnosed or undiagnosed HIV infection in the United States at
      the end of 2006. Nearly half of all U.S. HIV infections (48.1%) were found in men who have
      sex with men (MSM). Given the difficulty of maintaining behaviors that prevent HIV
      transmission over a lifetime and the occurrence of nonconsensual sex, the need for a safe and
      effective vaccine is clear. The primary purpose of this study is to determine the safety and
      efficacy of a VRC DNA/rAd5 vaccine regimen in healthy, at-risk, circumcised men and MTF
      transgender persons who have sex with men.

      Participants will be randomly assigned to one of two arms. Participants in Arm 1 will receive
      a recombinant DNA plasmid vaccine injection at study entry and on Days 28 and 56, followed by
      a recombinant adenoviral serotype vector vaccine injection on Day 168. Participants in Arm 2
      will receive placebo injections at study entry and on Days 28, 56, and 168.

      Participants who do not become HIV infected will be actively followed for a minimum of 24
      months and will continue to be followed by the study for long-term safety surveillance for a
      total of 5 years following enrollment. Participants will be contacted annually during the
      period of long-term safety surveillance.

      Participants who are found to be HIV infected prior to receiving their first injection or who
      receive their first injection but were HIV infected prior to study start will be followed on
      a modified schedule.

      Participants who become HIV infected will be followed for 6 months post-diagnosis.

      At most study visits, participants will undergo a physical exam and blood draw.

      NOTES:

      As of April 2013, all vaccinations in this study have been stopped. Participants have been
      notified of whether they received the study vaccines or placebo. Participants diagnosed with
      HIV infection will attend study visits for 6 months for health monitoring. Participants who
      are not diagnosed with HIV infection will attend planned study visits for 24 months and will
      be followed by the study clinic at least annually for a total of 5 years following study
      enrollment.

      As of June 2017, this study has been closed. Therefore, to avoid further burden on study
      participants, further participant follow-up for the study is suspended.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The trial was stopped for efficacy futility
  </why_stopped>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">October 6, 2017</completion_date>
  <primary_completion_date type="Actual">October 6, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participant Dropout Through Month 48</measure>
    <time_frame>Enrollment through Month 48 visit</time_frame>
    <description>For participants remaining uninfected, dropout is assessed only for primary follow-up, i.e. clinic visits. Protocol versions 4 and earlier included 24 months of primary follow-up, and versions 5 and later included 48 months. Participants may terminate early after completing primary follow-up, and participants who were found to be HIV-1 infected are analyzed as non-dropouts, so the number of dropouts and number of early terminations need not match.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participant Dropout Prior to Unblinding</measure>
    <time_frame>Enrollment until the date of dropout, through April 22, 2013 (up to Month 24 visit)</time_frame>
    <description>The trial was unblinded on April 23, 2013, and the protocol was in version 4 at the time.
For participants remaining uninfected, dropout is assessed only for primary follow-up, i.e. clinic visits. Protocol versions 4 and earlier included 24 months of primary follow-up, and versions 5 and later included 48 months. Participants may terminate early after completing primary follow-up, and participants who were found to be HIV-1 infected are analyzed as non-dropouts, so the number of dropouts and number of early terminations need not match.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participant Dropout After Unblinding</measure>
    <time_frame>April 23, 2013 through trial closure (up to Month 48 visit)</time_frame>
    <description>The trial was unblinded on April 23, 2013, and the protocol was in version 4 at the time.
For participants remaining uninfected, dropout is assessed only for primary follow-up, i.e. clinic visits. Protocol versions 4 and earlier included 24 months of primary follow-up, and versions 5 and later included 48 months. Participants may terminate early after completing primary follow-up, and participants who were found to be HIV-1 infected are analyzed as non-dropouts, so the number of dropouts and number of early terminations need not match.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HIV-1 Infections Diagnosed After Day 0 Including All Available Follow-up Through the Maximum Month 48 Visit</measure>
    <time_frame>Enrollment through Month 48 visit</time_frame>
    <description>For time-to-event analysis, an event is defined as HIV-1 infection and participants are censored if they dropped out early or completed the trial. HIV-1 diagnosis date is defined as the date of the earliest specimen collection yielding a positive HIV test. Participants remaining uninfected were censored at the latest specimen collection with a negative HIV-1 test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HIV-1 Infections Diagnosed After Day 0 Through the Month 24 Visit</measure>
    <time_frame>Enrollment through Month 24 visit</time_frame>
    <description>For time-to-event analysis, an event is defined as HIV-1 infection and participants remaining uninfected through the month 24 visit were censored. HIV-1 diagnosis date is defined as the date of the earliest specimen collection at or prior to month 24 which yielded a positive HIV test. Participants remaining uninfected through the month 24 visit were censored at the latest specimen collection with a negative HIV-1 test at or prior to the month 24 visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Experiencing Local Reactogenicity: Pain and/or Tenderness</measure>
    <time_frame>Through 3 days post each study vaccination, and to resolution for events present at the third day post vaccination</time_frame>
    <description>For each sign or symptom, we define the maximum observed grade for each participant over all vaccinations and post-vaccination assessments. Local and systemic signs and symptoms are assessed and graded based on The Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), Version 1.0, December, 2004 (Clarification dated August 2009). Local reactogenicity parameters are pain, tenderness, erythema, and induration. We present the maximum grade for pain and/or tenderness, and erythema and/or induration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Experiencing Local Reactogenicity: Erythema and/or Induration</measure>
    <time_frame>Through 3 days post each study vaccination, and to resolution for events present at the third day post vaccination</time_frame>
    <description>For each sign or symptom, we define the maximum observed grade for each participant over all vaccinations and post-vaccination assessments. Local and systemic signs and symptoms are assessed and graded based on The Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), Version 1.0, December, 2004 (Clarification dated August 2009). Local reactogenicity parameters are pain, tenderness, erythema, and induration. We present the maximum grade for pain and/or tenderness, and erythema and/or induration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Experiencing Systemic Reactogenicity</measure>
    <time_frame>Through 3 days post each study vaccination, and to resolution for events present at the third day post vaccination</time_frame>
    <description>For each sign or symptom, we define the maximum observed grade for each participant over all vaccinations and post-vaccination assessments. Local and systemic signs and symptoms are assessed and graded based on The Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), Version 1.0, December, 2004 (Clarification dated August 2009). Systemic reactogenicity parameters are malaise/fatigue, myalgia, headache, nausea, vomiting, chills, and arthralgia. We present the maximum grade calculated over these parameters.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2504</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a recombinant DNA plasmid vaccine injection at study entry and on Days 28 and 56, followed by a recombinant adenoviral serotype vector vaccine injection on Day 168. As of April 2013, all vaccinations in this study have been stopped.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a recombinant DNA plasmid vaccine placebo injection at study entry and on Days 28 and 56, followed by a recombinant adenoviral serotype vector vaccine placebo injection on Day 168. As of April 2013, all vaccinations in this study have been stopped.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DNA plasmid vaccine</intervention_name>
    <description>4-mg injection administered as 1 mL intramuscularly (IM) via Biojector® in either deltoid</description>
    <arm_group_label>1</arm_group_label>
    <other_name>VRC-HIVDNA016-00-VP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant adenoviral serotype 5 (rAD5) vector vaccine</intervention_name>
    <description>1 x 10^10 particle units (PU) administered as 1mL IM by needle and syringe in either deltoid</description>
    <arm_group_label>1</arm_group_label>
    <other_name>VRC-HIVADV014-00-VP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DNA vaccine placebo</intervention_name>
    <description>1 mL IM via Biojector® in either deltoid</description>
    <arm_group_label>2</arm_group_label>
    <other_name>VRC-PBSPLA043-00-VP</other_name>
    <other_name>phosphate buffered saline (PBS)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HIV-1 recombinant adenovirus vaccine placebo</intervention_name>
    <description>1 mL administered IM by needle and syringe in either deltoid</description>
    <arm_group_label>2</arm_group_label>
    <other_name>VRC-DILUENT013-DIL-VP</other_name>
    <other_name>final formulation buffer (FFB)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 and -2 negative

          -  Good general health

          -  Fully circumcised

          -  Experienced one or both of the following HIV risk criteria in the 6 months before
             study entry:

               1. Unprotected anal intercourse with one or more male or MTF transgender partner(s)

               2. Anal intercourse with two or more male or MTF transgender partners

          -  Alanine aminotransferase (ALT) 2.5 or less times the upper limit of normal (ULN)

          -  Ad5 neutralizing antibody (nAb) titer less than 1:18

          -  Have access to a participating study site and are willing to be followed during the
             study

          -  Demonstrate understanding of the study

          -  Willing to receive HIV test results

          -  Willing to discuss HIV infection risks and amenable to risk-reduction counseling

          -  Agrees not to enroll in another study of an investigational research agent before
             unblinding of this study

          -  NOTE: MTF transgender volunteers who have undergone gender reassignment surgery (GRS)
             are eligible to participate if they provide documentation from a health care provider
             confirming that they were fully circumcised prior to GRS. MTF transgender volunteers
             who have not undergone GRS are eligible to participate if they meet all enrollment
             criteria. Receipt of hormonal therapy does not make a transgender volunteer
             ineligible.

        Exclusion Criteria:

          -  HIV vaccines in prior HIV vaccine trial. Participants who can provide documentation
             that they received a placebo in a prior HIV trial may be eligible.

          -  Used antiretroviral (ARV) drugs for the purpose of HIV-1 prophylaxis for greater than
             or equal to 50% of days during the 3 months prior to first vaccination or for 30
             consecutive days within the 60 days prior to first vaccination

          -  Circumcised within 90 days prior to first vaccination or displays evidence that
             surgical site is not fully healed

          -  Immunosuppressive medications within 168 days prior to first study vaccination.
             Participants who have used corticosteroid nasal sprays for allergic rhinitis; topical
             corticosteroids for mild, uncomplicated dermatitis; or oral/parenteral corticosteroids
             for nonchronic conditions are not excluded.

          -  Blood products within 90 days prior to first study vaccination

          -  Immunoglobulin within 90 days prior to first study vaccination

          -  Live attenuated vaccines other than influenza vaccine within 30 days prior to first
             study vaccination

          -  Investigational research agents within 90 days prior to first study vaccination

          -  Influenza vaccine or any vaccines that are not live attenuated within 14 days prior to
             first study vaccination

          -  Allergy treatment with antigen injections within 30 days prior to first study
             vaccination or that are scheduled within 14 days after first vaccination

          -  Clinically significant medical condition, physical examination findings, abnormal
             laboratory results, or past medical history that, in the judgment of the investigator,
             has significant implications for current health

          -  Any medical, psychiatric, or job-related responsibility that would interfere with the
             study. More information about this criterion can be found in the protocol.

          -  Any concern that, in the opinion of the investigator, may interfere with a
             participant's completion of the post-vaccination symptom log

          -  History of serious adverse reactions to vaccinations, including anaphylaxis or allergy
             to any of the vaccine's components

          -  Current anti-tuberculosis prophylaxis or therapy

          -  Autoimmune disease. People with mild, stable, and uncomplicated autoimmune disease
             that does not require immunosuppressive medication and that, in the judgment of the
             site investigator, is likely not subject to exacerbation and likely not to complicate
             reactogenicity and adverse event assessments are not excluded.

          -  Immunodeficiency

          -  Bleeding disorder

          -  History of malignancy

          -  Seizure disorder. People with a history of seizures who have had no seizures within
             the 3 years prior to study entry are not excluded.

          -  Asthma other than mild, well-controlled asthma

          -  Hereditary angioedema (HAE), acquired angioedema (AAE), or idiopathic angioedema
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Hammer</last_name>
    <role>Study Chair</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Magdalena Sobieszczyk</last_name>
    <role>Study Chair</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Yin</last_name>
    <role>Study Chair</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama CRS</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The AIDS Research Alliance of America CRS</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA CARE Center CRS</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bridge HIV CRS</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital CRS</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Immunology Center CRS</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Hope Clinic of the Emory Vaccine Center CRS</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UIC Project WISH CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VRC Clinical Trials Core CRS</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital Vaccine CRS (BWH VCRS)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115-6110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fenway Health (FH) CRS</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215-4302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NY Univ. HIV/AIDS CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia P&amp;S CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032-3732</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Blood Center CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Vaccines to Prevent HIV Infection CRS</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Clinical Research Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn Prevention CRS</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Vaccine (VV) CRS</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-2582</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern CRS</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Vaccine Research Center CRS</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Care-Id Crs</name>
      <address>
        <city>Annandale</city>
        <state>Virginia</state>
        <zip>22003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Vaccine and Prevention CRS</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lu S. Immunogenicity of DNA vaccines in humans: it takes two to tango. Hum Vaccin. 2008 Nov-Dec;4(6):449-52. Epub 2008 Nov 28. Review.</citation>
    <PMID>18443427</PMID>
  </reference>
  <reference>
    <citation>Patterson S, Papagatsias T, Benlahrech A. Use of adenovirus in vaccines for HIV. Handb Exp Pharmacol. 2009;(188):275-93. doi: 10.1007/978-3-540-71029-5_13. Review.</citation>
    <PMID>19031031</PMID>
  </reference>
  <results_reference>
    <citation>Benmira S, Bhattacharya V, Schmid ML. An effective HIV vaccine: A combination of humoral and cellular immunity? Curr HIV Res. 2010 Sep;8(6):441-9. Review.</citation>
    <PMID>20636279</PMID>
  </results_reference>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>March 17, 2009</study_first_submitted>
  <study_first_submitted_qc>March 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2009</study_first_posted>
  <results_first_submitted>October 8, 2018</results_first_submitted>
  <results_first_submitted_qc>February 1, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 27, 2019</results_first_posted>
  <last_update_submitted>February 1, 2019</last_update_submitted>
  <last_update_submitted_qc>February 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV Seronegativity</keyword>
  <keyword>HIV Preventive Vaccine</keyword>
  <keyword>HIV Treatment Vaccine</keyword>
  <keyword>Adenovirus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 21, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/66/NCT00865566/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 3, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/66/NCT00865566/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vaccine</title>
          <description>Participants will receive a recombinant DNA plasmid vaccine injection at study entry and on Days 28 and 56, followed by a recombinant adenoviral serotype vector vaccine injection on Day 168. As of April 2013, all vaccinations in this study have been stopped.
DNA plasmid vaccine: 4-mg injection administered as 1 mL intramuscularly (IM) via Biojector® in either deltoid
Recombinant adenoviral serotype 5 (rAD5) vector vaccine: 1 x 10^10 particle units (PU) administered as 1mL IM by needle and syringe in either deltoid</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants will receive a recombinant DNA plasmid vaccine placebo injection at study entry and on Days 28 and 56, followed by a recombinant adenoviral serotype vector vaccine placebo injection on Day 168. As of April 2013, all vaccinations in this study have been stopped.
DNA vaccine placebo: 1 mL IM via Biojector® in either deltoid
HIV-1 recombinant adenovirus vaccine placebo: 1 mL administered IM by needle and syringe in either deltoid</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1253"/>
                <participants group_id="P2" count="1251"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Modified Intent-to-Treat Population</title>
              <participants_list>
                <participants group_id="P1" count="1251"/>
                <participants group_id="P2" count="1245"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="629"/>
                <participants group_id="P2" count="564"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="624"/>
                <participants group_id="P2" count="687"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="314"/>
                <participants group_id="P2" count="315"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="65"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant relocated</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
                <participants group_id="P2" count="107"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant unable to adhere</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other; N=245 due to early study closure</title>
              <participants_list>
                <participants group_id="P1" count="154"/>
                <participants group_id="P2" count="139"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>HIV infection</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All Enrolled Participants</population>
      <group_list>
        <group group_id="B1">
          <title>Vaccine</title>
          <description>Participants will receive a recombinant DNA plasmid vaccine injection at study entry and on Days 28 and 56, followed by a recombinant adenoviral serotype vector vaccine injection on Day 168. As of April 2013, all vaccinations in this study have been stopped.
DNA plasmid vaccine: 4-mg injection administered as 1 mL intramuscularly (IM) via Biojector® in either deltoid
Recombinant adenoviral serotype 5 (rAD5) vector vaccine: 1 x 10^10 particle units (PU) administered as 1mL IM by needle and syringe in either deltoid</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants will receive a recombinant DNA plasmid vaccine placebo injection at study entry and on Days 28 and 56, followed by a recombinant adenoviral serotype vector vaccine placebo injection on Day 168. As of April 2013, all vaccinations in this study have been stopped.
DNA vaccine placebo: 1 mL IM via Biojector® in either deltoid
HIV-1 recombinant adenovirus vaccine placebo: 1 mL administered IM by needle and syringe in either deltoid</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1253"/>
            <count group_id="B2" value="1251"/>
            <count group_id="B3" value="2504"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29" lower_limit="18" upper_limit="50"/>
                    <measurement group_id="B2" value="30" lower_limit="18" upper_limit="50"/>
                    <measurement group_id="B3" value="29" lower_limit="18" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>18-20 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>21-30 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="585"/>
                    <measurement group_id="B2" value="569"/>
                    <measurement group_id="B3" value="1154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>31-40 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="299"/>
                    <measurement group_id="B2" value="299"/>
                    <measurement group_id="B3" value="598"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>41-50 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="264"/>
                    <measurement group_id="B2" value="275"/>
                    <measurement group_id="B3" value="539"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <description>Self-reported gender identity</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1231"/>
                    <measurement group_id="B2" value="1229"/>
                    <measurement group_id="B3" value="2460"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transgender Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transgender Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1253"/>
                    <measurement group_id="B2" value="1251"/>
                    <measurement group_id="B3" value="2504"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="219"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1128"/>
                    <measurement group_id="B2" value="1157"/>
                    <measurement group_id="B3" value="2285"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="222"/>
                    <measurement group_id="B2" value="204"/>
                    <measurement group_id="B3" value="426"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="939"/>
                    <measurement group_id="B2" value="944"/>
                    <measurement group_id="B3" value="1883"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt;18.5 kg/m^2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18.5-24.9 kg/m^2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="550"/>
                    <measurement group_id="B2" value="586"/>
                    <measurement group_id="B3" value="1136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25.0-29.9 kg/m^2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="391"/>
                    <measurement group_id="B2" value="381"/>
                    <measurement group_id="B3" value="772"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30.0-34.9 kg/m^2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="189"/>
                    <measurement group_id="B2" value="167"/>
                    <measurement group_id="B3" value="356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>35-39.9 kg/m^2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=40 kg/m^2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing/Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of male sexual partners within 3 months prior to screening assessment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0</title>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="123"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="256"/>
                    <measurement group_id="B2" value="243"/>
                    <measurement group_id="B3" value="499"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="253"/>
                    <measurement group_id="B2" value="242"/>
                    <measurement group_id="B3" value="495"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3-4</title>
                  <measurement_list>
                    <measurement group_id="B1" value="349"/>
                    <measurement group_id="B2" value="367"/>
                    <measurement group_id="B3" value="716"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5 or more</title>
                  <measurement_list>
                    <measurement group_id="B1" value="330"/>
                    <measurement group_id="B2" value="327"/>
                    <measurement group_id="B3" value="657"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of male sexual partners within 3 months prior to screening assessment</title>
          <description>Self-reported at screening</description>
          <units>partners</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3" lower_limit="0" upper_limit="125"/>
                    <measurement group_id="B2" value="3" lower_limit="0" upper_limit="70"/>
                    <measurement group_id="B3" value="3" lower_limit="0" upper_limit="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Any unprotected receptive anal sex with a partner within 3 months prior to screening assessment</title>
          <description>Self-reported at screening</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="589"/>
                    <measurement group_id="B2" value="573"/>
                    <measurement group_id="B3" value="1162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participant Dropout Through Month 48</title>
        <description>For participants remaining uninfected, dropout is assessed only for primary follow-up, i.e. clinic visits. Protocol versions 4 and earlier included 24 months of primary follow-up, and versions 5 and later included 48 months. Participants may terminate early after completing primary follow-up, and participants who were found to be HIV-1 infected are analyzed as non-dropouts, so the number of dropouts and number of early terminations need not match.</description>
        <time_frame>Enrollment through Month 48 visit</time_frame>
        <population>MITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine</title>
            <description>Participants will receive a recombinant DNA plasmid vaccine injection at study entry and on Days 28 and 56, followed by a recombinant adenoviral serotype vector vaccine injection on Day 168. As of April 2013, all vaccinations in this study have been stopped.
DNA plasmid vaccine: 4-mg injection administered as 1 mL intramuscularly (IM) via Biojector® in either deltoid
Recombinant adenoviral serotype 5 (rAD5) vector vaccine: 1 x 10^10 particle units (PU) administered as 1mL IM by needle and syringe in either deltoid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive a recombinant DNA plasmid vaccine placebo injection at study entry and on Days 28 and 56, followed by a recombinant adenoviral serotype vector vaccine placebo injection on Day 168. As of April 2013, all vaccinations in this study have been stopped.
DNA vaccine placebo: 1 mL IM via Biojector® in either deltoid
HIV-1 recombinant adenovirus vaccine placebo: 1 mL administered IM by needle and syringe in either deltoid</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Dropout Through Month 48</title>
          <description>For participants remaining uninfected, dropout is assessed only for primary follow-up, i.e. clinic visits. Protocol versions 4 and earlier included 24 months of primary follow-up, and versions 5 and later included 48 months. Participants may terminate early after completing primary follow-up, and participants who were found to be HIV-1 infected are analyzed as non-dropouts, so the number of dropouts and number of early terminations need not match.</description>
          <population>MITT population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1251"/>
                <count group_id="O2" value="1245"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="340"/>
                    <measurement group_id="O2" value="436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cox proportional hazards model to assess the association between treatment assignment and dropout</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Score test</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>0.84</ci_upper_limit>
            <estimate_desc>HR is vaccine / placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participant Dropout Prior to Unblinding</title>
        <description>The trial was unblinded on April 23, 2013, and the protocol was in version 4 at the time.
For participants remaining uninfected, dropout is assessed only for primary follow-up, i.e. clinic visits. Protocol versions 4 and earlier included 24 months of primary follow-up, and versions 5 and later included 48 months. Participants may terminate early after completing primary follow-up, and participants who were found to be HIV-1 infected are analyzed as non-dropouts, so the number of dropouts and number of early terminations need not match.</description>
        <time_frame>Enrollment until the date of dropout, through April 22, 2013 (up to Month 24 visit)</time_frame>
        <population>MITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine</title>
            <description>Participants will receive a recombinant DNA plasmid vaccine injection at study entry and on Days 28 and 56, followed by a recombinant adenoviral serotype vector vaccine injection on Day 168. As of April 2013, all vaccinations in this study have been stopped.
DNA plasmid vaccine: 4-mg injection administered as 1 mL intramuscularly (IM) via Biojector® in either deltoid
Recombinant adenoviral serotype 5 (rAD5) vector vaccine: 1 x 10^10 particle units (PU) administered as 1mL IM by needle and syringe in either deltoid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive a recombinant DNA plasmid vaccine placebo injection at study entry and on Days 28 and 56, followed by a recombinant adenoviral serotype vector vaccine placebo injection on Day 168. As of April 2013, all vaccinations in this study have been stopped.
DNA vaccine placebo: 1 mL IM via Biojector® in either deltoid
HIV-1 recombinant adenovirus vaccine placebo: 1 mL administered IM by needle and syringe in either deltoid</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Dropout Prior to Unblinding</title>
          <description>The trial was unblinded on April 23, 2013, and the protocol was in version 4 at the time.
For participants remaining uninfected, dropout is assessed only for primary follow-up, i.e. clinic visits. Protocol versions 4 and earlier included 24 months of primary follow-up, and versions 5 and later included 48 months. Participants may terminate early after completing primary follow-up, and participants who were found to be HIV-1 infected are analyzed as non-dropouts, so the number of dropouts and number of early terminations need not match.</description>
          <population>MITT population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1251"/>
                <count group_id="O2" value="1245"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cox PH model to assess the association between treatment assignment and dropout</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <p_value_desc>Score test</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>1</ci_upper_limit>
            <estimate_desc>HR is vaccine / placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participant Dropout After Unblinding</title>
        <description>The trial was unblinded on April 23, 2013, and the protocol was in version 4 at the time.
For participants remaining uninfected, dropout is assessed only for primary follow-up, i.e. clinic visits. Protocol versions 4 and earlier included 24 months of primary follow-up, and versions 5 and later included 48 months. Participants may terminate early after completing primary follow-up, and participants who were found to be HIV-1 infected are analyzed as non-dropouts, so the number of dropouts and number of early terminations need not match.</description>
        <time_frame>April 23, 2013 through trial closure (up to Month 48 visit)</time_frame>
        <population>MITT population participants who were HIV-uninfected and on-study as of April 23, 2013</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine</title>
            <description>Participants will receive a recombinant DNA plasmid vaccine injection at study entry and on Days 28 and 56, followed by a recombinant adenoviral serotype vector vaccine injection on Day 168. As of April 2013, all vaccinations in this study have been stopped.
DNA plasmid vaccine: 4-mg injection administered as 1 mL intramuscularly (IM) via Biojector® in either deltoid
Recombinant adenoviral serotype 5 (rAD5) vector vaccine: 1 x 10^10 particle units (PU) administered as 1mL IM by needle and syringe in either deltoid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive a recombinant DNA plasmid vaccine placebo injection at study entry and on Days 28 and 56, followed by a recombinant adenoviral serotype vector vaccine placebo injection on Day 168. As of April 2013, all vaccinations in this study have been stopped.
DNA vaccine placebo: 1 mL IM via Biojector® in either deltoid
HIV-1 recombinant adenovirus vaccine placebo: 1 mL administered IM by needle and syringe in either deltoid</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Dropout After Unblinding</title>
          <description>The trial was unblinded on April 23, 2013, and the protocol was in version 4 at the time.
For participants remaining uninfected, dropout is assessed only for primary follow-up, i.e. clinic visits. Protocol versions 4 and earlier included 24 months of primary follow-up, and versions 5 and later included 48 months. Participants may terminate early after completing primary follow-up, and participants who were found to be HIV-1 infected are analyzed as non-dropouts, so the number of dropouts and number of early terminations need not match.</description>
          <population>MITT population participants who were HIV-uninfected and on-study as of April 23, 2013</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1036"/>
                <count group_id="O2" value="999"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="241"/>
                    <measurement group_id="O2" value="309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Assess the association between treatment assignment and dropout</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Score test</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>0.84</ci_upper_limit>
            <estimate_desc>HR is vaccine / placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HIV-1 Infections Diagnosed After Day 0 Including All Available Follow-up Through the Maximum Month 48 Visit</title>
        <description>For time-to-event analysis, an event is defined as HIV-1 infection and participants are censored if they dropped out early or completed the trial. HIV-1 diagnosis date is defined as the date of the earliest specimen collection yielding a positive HIV test. Participants remaining uninfected were censored at the latest specimen collection with a negative HIV-1 test.</description>
        <time_frame>Enrollment through Month 48 visit</time_frame>
        <population>Modified Intent-to-Treat Cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine</title>
            <description>Participants will receive a recombinant DNA plasmid vaccine injection at study entry and on Days 28 and 56, followed by a recombinant adenoviral serotype vector vaccine injection on Day 168. As of April 2013, all vaccinations in this study have been stopped.
DNA plasmid vaccine: 4-mg injection administered as 1 mL intramuscularly (IM) via Biojector® in either deltoid
Recombinant adenoviral serotype 5 (rAD5) vector vaccine: 1 x 10^10 particle units (PU) administered as 1mL IM by needle and syringe in either deltoid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive a recombinant DNA plasmid vaccine placebo injection at study entry and on Days 28 and 56, followed by a recombinant adenoviral serotype vector vaccine placebo injection on Day 168. As of April 2013, all vaccinations in this study have been stopped.
DNA vaccine placebo: 1 mL IM via Biojector® in either deltoid
HIV-1 recombinant adenovirus vaccine placebo: 1 mL administered IM by needle and syringe in either deltoid</description>
          </group>
        </group_list>
        <measure>
          <title>HIV-1 Infections Diagnosed After Day 0 Including All Available Follow-up Through the Maximum Month 48 Visit</title>
          <description>For time-to-event analysis, an event is defined as HIV-1 infection and participants are censored if they dropped out early or completed the trial. HIV-1 diagnosis date is defined as the date of the earliest specimen collection yielding a positive HIV test. Participants remaining uninfected were censored at the latest specimen collection with a negative HIV-1 test.</description>
          <population>Modified Intent-to-Treat Cohort</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1251"/>
                <count group_id="O2" value="1245"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.903</p_value>
            <p_value_desc>Score test</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>Adjusted for age, behavioral risk score, square of behavioral risk score, race, and BMI</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>1.42</ci_upper_limit>
            <estimate_desc>HR is vaccine / placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HIV-1 Infections Diagnosed After Day 0 Through the Month 24 Visit</title>
        <description>For time-to-event analysis, an event is defined as HIV-1 infection and participants remaining uninfected through the month 24 visit were censored. HIV-1 diagnosis date is defined as the date of the earliest specimen collection at or prior to month 24 which yielded a positive HIV test. Participants remaining uninfected through the month 24 visit were censored at the latest specimen collection with a negative HIV-1 test at or prior to the month 24 visit.</description>
        <time_frame>Enrollment through Month 24 visit</time_frame>
        <population>Modified Intent-to-Treat Cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine</title>
            <description>Participants will receive a recombinant DNA plasmid vaccine injection at study entry and on Days 28 and 56, followed by a recombinant adenoviral serotype vector vaccine injection on Day 168. As of April 2013, all vaccinations in this study have been stopped.
DNA plasmid vaccine: 4-mg injection administered as 1 mL intramuscularly (IM) via Biojector® in either deltoid
Recombinant adenoviral serotype 5 (rAD5) vector vaccine: 1 x 10^10 particle units (PU) administered as 1mL IM by needle and syringe in either deltoid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive a recombinant DNA plasmid vaccine placebo injection at study entry and on Days 28 and 56, followed by a recombinant adenoviral serotype vector vaccine placebo injection on Day 168. As of April 2013, all vaccinations in this study have been stopped.
DNA vaccine placebo: 1 mL IM via Biojector® in either deltoid
HIV-1 recombinant adenovirus vaccine placebo: 1 mL administered IM by needle and syringe in either deltoid</description>
          </group>
        </group_list>
        <measure>
          <title>HIV-1 Infections Diagnosed After Day 0 Through the Month 24 Visit</title>
          <description>For time-to-event analysis, an event is defined as HIV-1 infection and participants remaining uninfected through the month 24 visit were censored. HIV-1 diagnosis date is defined as the date of the earliest specimen collection at or prior to month 24 which yielded a positive HIV test. Participants remaining uninfected through the month 24 visit were censored at the latest specimen collection with a negative HIV-1 test at or prior to the month 24 visit.</description>
          <population>Modified Intent-to-Treat Cohort</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1251"/>
                <count group_id="O2" value="1245"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.783</p_value>
            <p_value_desc>Adjusted for ave, behavioral risk score, square of behavioral risk score, and BMI</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>Score test</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>1.58</ci_upper_limit>
            <estimate_desc>HR is vaccine / placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Experiencing Local Reactogenicity: Pain and/or Tenderness</title>
        <description>For each sign or symptom, we define the maximum observed grade for each participant over all vaccinations and post-vaccination assessments. Local and systemic signs and symptoms are assessed and graded based on The Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), Version 1.0, December, 2004 (Clarification dated August 2009). Local reactogenicity parameters are pain, tenderness, erythema, and induration. We present the maximum grade for pain and/or tenderness, and erythema and/or induration.</description>
        <time_frame>Through 3 days post each study vaccination, and to resolution for events present at the third day post vaccination</time_frame>
        <population>All Enrolled Participants</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine</title>
            <description>Participants will receive a recombinant DNA plasmid vaccine injection at study entry and on Days 28 and 56, followed by a recombinant adenoviral serotype vector vaccine injection on Day 168. As of April 2013, all vaccinations in this study have been stopped.
DNA plasmid vaccine: 4-mg injection administered as 1 mL intramuscularly (IM) via Biojector® in either deltoid
Recombinant adenoviral serotype 5 (rAD5) vector vaccine: 1 x 10^10 particle units (PU) administered as 1mL IM by needle and syringe in either deltoid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive a recombinant DNA plasmid vaccine placebo injection at study entry and on Days 28 and 56, followed by a recombinant adenoviral serotype vector vaccine placebo injection on Day 168. As of April 2013, all vaccinations in this study have been stopped.
DNA vaccine placebo: 1 mL IM via Biojector® in either deltoid
HIV-1 recombinant adenovirus vaccine placebo: 1 mL administered IM by needle and syringe in either deltoid</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Local Reactogenicity: Pain and/or Tenderness</title>
          <description>For each sign or symptom, we define the maximum observed grade for each participant over all vaccinations and post-vaccination assessments. Local and systemic signs and symptoms are assessed and graded based on The Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), Version 1.0, December, 2004 (Clarification dated August 2009). Local reactogenicity parameters are pain, tenderness, erythema, and induration. We present the maximum grade for pain and/or tenderness, and erythema and/or induration.</description>
          <population>All Enrolled Participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1253"/>
                <count group_id="O2" value="1251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="138"/>
                    <measurement group_id="O2" value="415"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="723"/>
                    <measurement group_id="O2" value="744"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="370"/>
                    <measurement group_id="O2" value="90"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Potentially life-threatening</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Experiencing Local Reactogenicity: Erythema and/or Induration</title>
        <description>For each sign or symptom, we define the maximum observed grade for each participant over all vaccinations and post-vaccination assessments. Local and systemic signs and symptoms are assessed and graded based on The Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), Version 1.0, December, 2004 (Clarification dated August 2009). Local reactogenicity parameters are pain, tenderness, erythema, and induration. We present the maximum grade for pain and/or tenderness, and erythema and/or induration.</description>
        <time_frame>Through 3 days post each study vaccination, and to resolution for events present at the third day post vaccination</time_frame>
        <population>All enrolled participants</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine</title>
            <description>Participants will receive a recombinant DNA plasmid vaccine injection at study entry and on Days 28 and 56, followed by a recombinant adenoviral serotype vector vaccine injection on Day 168. As of April 2013, all vaccinations in this study have been stopped.
DNA plasmid vaccine: 4-mg injection administered as 1 mL intramuscularly (IM) via Biojector® in either deltoid
Recombinant adenoviral serotype 5 (rAD5) vector vaccine: 1 x 10^10 particle units (PU) administered as 1mL IM by needle and syringe in either deltoid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive a recombinant DNA plasmid vaccine placebo injection at study entry and on Days 28 and 56, followed by a recombinant adenoviral serotype vector vaccine placebo injection on Day 168. As of April 2013, all vaccinations in this study have been stopped.
DNA vaccine placebo: 1 mL IM via Biojector® in either deltoid
HIV-1 recombinant adenovirus vaccine placebo: 1 mL administered IM by needle and syringe in either deltoid</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Local Reactogenicity: Erythema and/or Induration</title>
          <description>For each sign or symptom, we define the maximum observed grade for each participant over all vaccinations and post-vaccination assessments. Local and systemic signs and symptoms are assessed and graded based on The Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), Version 1.0, December, 2004 (Clarification dated August 2009). Local reactogenicity parameters are pain, tenderness, erythema, and induration. We present the maximum grade for pain and/or tenderness, and erythema and/or induration.</description>
          <population>All enrolled participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1253"/>
                <count group_id="O2" value="1251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="717"/>
                    <measurement group_id="O2" value="980"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;0 to 25 square cm</title>
                  <measurement_list>
                    <measurement group_id="O1" value="498"/>
                    <measurement group_id="O2" value="268"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;25 to 81 square cm (grade 1)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;9 cm any diameter (grade 2)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;81 square cm (grade 2)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Experiencing Systemic Reactogenicity</title>
        <description>For each sign or symptom, we define the maximum observed grade for each participant over all vaccinations and post-vaccination assessments. Local and systemic signs and symptoms are assessed and graded based on The Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), Version 1.0, December, 2004 (Clarification dated August 2009). Systemic reactogenicity parameters are malaise/fatigue, myalgia, headache, nausea, vomiting, chills, and arthralgia. We present the maximum grade calculated over these parameters.</description>
        <time_frame>Through 3 days post each study vaccination, and to resolution for events present at the third day post vaccination</time_frame>
        <population>All enrolled participants</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine</title>
            <description>Participants will receive a recombinant DNA plasmid vaccine injection at study entry and on Days 28 and 56, followed by a recombinant adenoviral serotype vector vaccine injection on Day 168. As of April 2013, all vaccinations in this study have been stopped.
DNA plasmid vaccine: 4-mg injection administered as 1 mL intramuscularly (IM) via Biojector® in either deltoid
Recombinant adenoviral serotype 5 (rAD5) vector vaccine: 1 x 10^10 particle units (PU) administered as 1mL IM by needle and syringe in either deltoid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive a recombinant DNA plasmid vaccine placebo injection at study entry and on Days 28 and 56, followed by a recombinant adenoviral serotype vector vaccine placebo injection on Day 168. As of April 2013, all vaccinations in this study have been stopped.
DNA vaccine placebo: 1 mL IM via Biojector® in either deltoid
HIV-1 recombinant adenovirus vaccine placebo: 1 mL administered IM by needle and syringe in either deltoid</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Systemic Reactogenicity</title>
          <description>For each sign or symptom, we define the maximum observed grade for each participant over all vaccinations and post-vaccination assessments. Local and systemic signs and symptoms are assessed and graded based on The Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), Version 1.0, December, 2004 (Clarification dated August 2009). Systemic reactogenicity parameters are malaise/fatigue, myalgia, headache, nausea, vomiting, chills, and arthralgia. We present the maximum grade calculated over these parameters.</description>
          <population>All enrolled participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1253"/>
                <count group_id="O2" value="1251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="563"/>
                    <measurement group_id="O2" value="667"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="408"/>
                    <measurement group_id="O2" value="406"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="240"/>
                    <measurement group_id="O2" value="169"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Potentially life-threatening</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Reporting of all AEs occurred during 2 periods for each participant: 1) from enrollment through 28 days after the third vaccination, and 2) from the fourth vaccination through 28 days after the fourth vaccination. Between and after these time periods, only SAEs, new chronic conditions requiring medical intervention of more than 30 days, and newly diagnosed/treated STIs were reported. Events requiring expedited reporting (protocol section 12.3) were reported through the study, up to 60 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Vaccine</title>
          <description>Participants will receive a recombinant DNA plasmid vaccine injection at study entry and on Days 28 and 56, followed by a recombinant adenoviral serotype vector vaccine injection on Day 168. As of April 2013, all vaccinations in this study have been stopped.
DNA plasmid vaccine: 4-mg injection administered as 1 mL intramuscularly (IM) via Biojector® in either deltoid
Recombinant adenoviral serotype 5 (rAD5) vector vaccine: 1 x 10^10 particle units (PU) administered as 1mL IM by needle and syringe in either deltoid</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants will receive a recombinant DNA plasmid vaccine placebo injection at study entry and on Days 28 and 56, followed by a recombinant adenoviral serotype vector vaccine placebo injection on Day 168. As of April 2013, all vaccinations in this study have been stopped.
DNA vaccine placebo: 1 mL IM via Biojector® in either deltoid
HIV-1 recombinant adenovirus vaccine placebo: 1 mL administered IM by needle and syringe in either deltoid</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="95" subjects_at_risk="1251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Any event in SOC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Anaemias NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Any event in SOC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Ischaemic coronary artery disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Coronary artery disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Heart failures NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Supraventricular arrhythmias</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmias and cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Any event in SOC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Haemoglobinopathies congenital</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Any event in SOC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Colitis (excl infective)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Acute and chronic pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Duodenal ulcers and perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Intestinal ulcers and perforation NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Abdominal hernias NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Gastric ulcers and perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Gastrointestinal atonic and hypomotility disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stenosis and obstruction NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Non-site specific gastrointestinal haemorrhages</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcers and perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Rectal inflammations NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Any event in SOC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Pain and discomfort NEC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Death and sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Withdrawal and rebound effects</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Any event in SOC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Acute and chronic sarcoidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Allergies to foods, food additives, drugs and other chemicals</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Any event in SOC</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Abdominal and gastrointestinal infections</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Bacterial infections NEC</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Infections NEC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract and lung infections</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infections</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Clostridia infections</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Sepsis, bacteraemia, viraemia and fungaemia NEC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Skin structures and soft tissue infections</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Staphylococcal infections</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Streptococcal infections</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Bone and joint infections</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Borrelial infections</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Breast infections</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Herpes viral infections</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Infectious disorders carrier</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Urinary tract infections</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Viral infections NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Any event in SOC</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Limb fractures and dislocations</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Skull fractures, facial bone fractures and dislocations</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Non-site specific injuries NEC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Overdoses NEC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Poisoning and toxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Site specific injuries NEC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Skin injuries NEC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Spinal fractures and dislocations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Abdominal injuries NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Cardiac and vascular procedural complications</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Cardiovascular injuries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Cerebral injuries NEC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Muscle, tendon and ligament injuries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Pathways and sources of exposure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Thermal burns</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Any event in SOC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Liver function analyses</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Metabolism tests NEC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Any event in SOC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Potassium imbalance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Any event in SOC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Bursal disorders</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Muscle weakness conditions</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Myopathies</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Any event in SOC</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Prostatic neoplasms malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Colorectal neoplasms malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Gastric neoplasms malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Leukaemias acute lymphocytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Testicular neoplasms malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasms malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Any event in SOC</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Seizures and seizure disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Central nervous system haemorrhages and cerebrovascular accidents</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Encephalopathies NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Mononeuropathies</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Neurological signs and symptoms NEC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Optic nerve disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Transient cerebrovascular events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Any event in SOC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Device malfunction events NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Any event in SOC</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Suicidal and self-injurious behaviour</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Depressive disorders</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Substance related and addictive disorders</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Bipolar disorders</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Anxiety symptoms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Psychotic disorder NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Confusion and disorientation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Mental disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Schizoaffective and schizophreniform disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Schizophrenia NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Somatic symptom disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Any event in SOC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Renal failure and impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Renal lithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Any event in SOC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Testicular and epididymal disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Any event in SOC</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Pulmonary thrombotic and embolic conditions</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Pneumothorax and pleural effusions NEC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Any event in SOC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue ulcerations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Any event in SOC</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Peripheral embolism and thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Non-site specific necrosis and vascular insufficiency NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Vascular hypertensive disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Vascular hypotensive disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="833" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="828" subjects_at_risk="1251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Any event in SOC</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Lymphatic system disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Anaemias NEC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Leukocytoses NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Red blood cell abnormal findings NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Spleen disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Any event in SOC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Supraventricular arrhythmias</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Cardiac signs and symptoms NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Rate and rhythm disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Any event in SOC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Male reproductive tract disorders congenital</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Any event in SOC</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Ear disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Inner ear signs and symptoms</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>External ear disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Middle ear disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Eustachian tube disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Hearing losses</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Tympanic membrane disorders (excl infections)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Any event in SOC</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Thyroid hypofunction disorders</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Endocrine abnormalities of gonadal function NEC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Male gonadal function disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Thyroid hyperfunction disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Any event in SOC</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Lid, lash and lacrimal infections, irritations and inflammations</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Ocular disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Conjunctival and corneal bleeding and vascular disorders</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Ocular sensation disorders</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Visual disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Conjunctival infections, irritations and inflammations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Eyelid movement disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Lacrimation disorders</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Ocular infections, inflammations and associated manifestations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Blindness (excl colour blindness)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Glaucomas (excl congenital)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Refractive and accommodative disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Retinal, choroid and vitreous infections and inflammations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Any event in SOC</sub_title>
                <counts group_id="E1" subjects_affected="149" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="146" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Diarrhoea (excl infective)</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Nausea and vomiting symptoms</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Gastrointestinal and abdominal pains (excl oral and throat)</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Stomatitis and ulceration</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Gastrointestinal atonic and hypomotility disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Haemorrhoids and gastrointestinal varices (excl oesophageal)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Anal and rectal disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Gastrointestinal signs and symptoms NEC</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Dental pain and sensation disorders</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Dyspeptic signs and symptoms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhages</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Gastritis (excl infective)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Colitis (excl infective)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Non-site specific gastrointestinal haemorrhages</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Abdominal hernias NEC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Anal and rectal signs and symptoms</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Dental and periodontal infections and inflammations</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Diaphragmatic hernias</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Flatulence, bloating and distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Gingival disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Gingival haemorrhages</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcers and perforation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Tongue disorders</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Tongue signs and symptoms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Benign neoplasms gastrointestinal (excl oral cavity)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammatory disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Oral dryness and saliva altered</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Abdominal findings abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Anal and rectal pains</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Dental disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Faecal abnormalities NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Gastrointestinal dyskinetic disorders</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Gastrointestinal fistulae</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Inguinal hernias</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Oral soft tissue pain and paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Peptic ulcers and perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Rectal inflammations NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Any event in SOC</sub_title>
                <counts group_id="E1" subjects_affected="138" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="104" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Injection site reactions</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Asthenic conditions</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Febrile disorders</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Feelings and sensations NEC</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>General signs and symptoms NEC</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Pain and discomfort NEC</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Administration site reactions NEC</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Oedema NEC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Therapeutic and nontherapeutic responses</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Vaccination site reactions</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Mass conditions NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Withdrawal and rebound effects</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Inflammations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Any event in SOC</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Hepatocellular damage and hepatitis NEC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Cholecystitis and cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Cholestasis and jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Hepatobiliary signs and symptoms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Any event in SOC</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Atopic disorders</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Allergies to foods, food additives, drugs and other chemicals</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Allergic conditions NEC</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Anaphylactic and anaphylactoid responses</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Any event in SOC</sub_title>
                <counts group_id="E1" subjects_affected="531" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="549" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infections</sub_title>
                <counts group_id="E1" subjects_affected="275" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="254" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Neisseria infections</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="83" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Viral infections NEC</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Chlamydial infections</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Treponema infections</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Abdominal and gastrointestinal infections</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Herpes viral infections</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Streptococcal infections</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Urinary tract infections</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract and lung infections</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Papilloma viral infections</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Bacterial infections NEC</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Eye and eyelid infections</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Skin structures and soft tissue infections</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Dental and oral soft tissue infections</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Ectoparasitic infestations</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Ear infections</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Staphylococcal infections</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Tinea infections</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Influenza viral infections</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Infections NEC</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Male reproductive tract infections</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Fungal infections NEC</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Hepatitis viral infections</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Candida infections</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Molluscum contagiosum viral infections</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Epstein-Barr viral infections</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Giardia infections</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Tuberculous infections</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Amoebic infections</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Bone and joint infections</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Caliciviral infections</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Clostridia infections</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Coxsackie viral infections</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Cytomegaloviral infections</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Escherichia infections</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Haemophilus infections</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Helicobacter infections</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Nematode infections</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Any event in SOC</sub_title>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="101" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Skin injuries NEC</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Muscle, tendon and ligament injuries</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Non-site specific injuries NEC</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Non-site specific procedural complications</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Limb fractures and dislocations</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Site specific injuries NEC</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Neurological and psychiatric procedural complications</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Bone and joint injuries NEC</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Thermal burns</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Exposures to agents or circumstances NEC</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Radiation injuries</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Cerebral injuries NEC</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Fractures and dislocations NEC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Eye injuries NEC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Skull fractures, facial bone fractures and dislocations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Thoracic cage fractures and dislocations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Chest and lung injuries NEC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Gastrointestinal and hepatobiliary procedural complications</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Ear injuries NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Overdoses NEC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Poisoning and toxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Reproductive system and breast injuries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Spinal fractures and dislocations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Vaccination related complications</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Any event in SOC</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Vascular tests NEC (incl blood pressure)</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Reproductive hormone analyses</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Liver function analyses</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Red blood cell analyses</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Carbohydrate tolerance analyses (incl diabetes)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Digestive enzymes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Mineral and electrolyte analyses</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Platelet analyses</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Bacteria identification and serology (excl mycobacteria)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Cardiac auscultatory investigations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Coagulation and bleeding analyses</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Heart rate and pulse investigations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Investigations NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Musculoskeletal and soft tissue tests NEC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Mycobacteria identification and serology</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Tissue enzyme analyses NEC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>White blood cell analyses</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Any event in SOC</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus (incl subtypes)</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Fat soluble vitamin deficiencies and disorders</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Appetite disorders</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Elevated cholesterol</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Disorders of purine metabolism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>General nutritional disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Potassium imbalance</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Fluid intake increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Food malabsorption and intolerance syndromes (excl sugar intolerance)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Lipid metabolism and deposit disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Water soluble vitamin deficiencies</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Elevated triglycerides</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemias NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic conditions NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Magnesium metabolism disorders</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Protein metabolism disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Sugar intolerance (excl glucose intolerance)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Total fluid volume decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Any event in SOC</sub_title>
                <counts group_id="E1" subjects_affected="97" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="107" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Musculoskeletal and connective tissue pain and discomfort</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Muscle pains</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Joint related signs and symptoms</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Muscle related signs and symptoms NEC</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Tendon disorders</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Bone related signs and symptoms</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Arthropathies NEC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Bone disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Bursal disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Muscle weakness conditions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Muscle tone abnormalities</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Cartilage disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Extremity deformities</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Joint related disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Musculoskeletal and connective tissue infections and inflammations NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Osteoarthropathies</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthropathies</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Soft tissue disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Synovial disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Any event in SOC</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Skin neoplasms benign</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Lip and oral cavity neoplasms benign</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Skin neoplasms malignant and unspecified (excl melanoma)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Soft tissue neoplasms benign NEC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Nervous system neoplasms benign NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Reproductive neoplasms male benign NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Any event in SOC</sub_title>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Headaches NEC</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Neurological signs and symptoms NEC</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Paraesthesias and dysaesthesias</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Migraine headaches</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Sensory abnormalities NEC</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Disturbances in consciousness NEC</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Mononeuropathies</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Peripheral neuropathies NEC</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Lumbar spinal cord and nerve root disorders</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Narcolepsy and hypersomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Seizures and seizure disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Cervical spinal cord and nerve root disorders</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Coordination and balance disturbances</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Disturbances in sleep phase rhythm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Facial cranial nerve disorders</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Memory loss (excl dementia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Mental impairment (excl dementia and memory loss)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Neurologic visual problems NEC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Sleep disturbances NEC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Any event in SOC</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Depressive disorders</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Anxiety symptoms</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Disturbances in initiating and maintaining sleep</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Substance related and addictive disorders</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Attention deficit and disruptive behaviour disorders</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Anxiety disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Bipolar disorders</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Panic attacks and disorders</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Sexual desire disorders</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Stress disorders</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Emotional and mood disturbances NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Schizophrenia NEC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Behaviour and socialisation disturbances</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Fear symptoms and phobic disorders (incl social phobia)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Fluctuating mood symptoms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Mental disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Mood alterations with depressive symptoms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Mood disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Schizoaffective and schizophreniform disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Sleep disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Somatic symptom disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Suicidal and self-injurious behaviour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Any event in SOC</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Bladder and urethral symptoms</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Renal lithiasis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Urethral disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Urinary abnormalities</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Urinary tract signs and symptoms NEC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Bladder neoplasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Any event in SOC</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Penile disorders NEC (excl erection and ejaculation)</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Reproductive tract signs and symptoms NEC</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Erection and ejaculation conditions and disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Prostate and seminal vesicles infections and inflammations</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Reproductive tract disorders NEC (excl neoplasms)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Testicular and epididymal disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Breast signs and symptoms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Scrotal disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Breast disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Pelvic prolapse conditions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Sexual function and fertility disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Spermatogenesis and semen disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Testicular and epididymal neoplasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Any event in SOC</sub_title>
                <counts group_id="E1" subjects_affected="123" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="95" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract signs and symptoms</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Coughing and associated symptoms</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Nasal congestion and inflammations</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Paranasal sinus disorders (excl infections and neoplasms)</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Bronchospasm and obstruction</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Pharyngeal disorders (excl infections and neoplasms)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Breathing abnormalities</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Nasal disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Respiratory tract disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Laryngeal and adjacent sites disorders NEC (excl infections and neoplasms)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Pulmonary oedemas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Respiratory failures (excl neonatal)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Any event in SOC</sub_title>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Dermatitis and eczema</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Rashes, eruptions and exanthems NEC</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Apocrine and eccrine gland disorders</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Dermal and epidermal conditions NEC</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Pruritus NEC</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Erythemas</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Psoriatic conditions</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Acnes</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Angioedemas</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Bullous conditions</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Papulosquamous conditions</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Pilar disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Purpura and related conditions</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue ulcerations</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Skin cysts and polyps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Skin preneoplastic conditions NEC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Alopecias</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Dermatitis ascribed to specific agent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Hyperkeratoses</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Hyperpigmentation disorders</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Photosensitivity and photodermatosis conditions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Rosaceas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Any event in SOC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Crime victims</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Any event in SOC</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Vascular hypertensive disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Haemorrhages NEC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Lymphoedemas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1251"/>
              </event>
              <event>
                <sub_title>Peripheral embolism and thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1251"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jessica Andriesen, PhD, Associate Director of HVTN SDMC Operations</name_or_title>
      <organization>Fred Hutchinson Cancer Research Center</organization>
      <phone>206-667-5812</phone>
      <email>jandries@fredhutch.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

